Fentanyl transdermal patch
Executive SummaryAgreement between Cygnus and Anaquest gives latter exclusive North American marketing rights. Cygnus has been developing the patch for the past 18 months, and Anaquest plans to begin clinical in February 1989. The 24-hour patch product is expected to be used for "post operative pain management and relief for terminally ill patients suffering severe chronic pain." Alza filed an NDA for its fentanyl patch product in December 1987.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.